As aforementioned, combined blockage of MEK+BCL-XL/BCL2 is currently explored in two clinical trials, for patients with advanced or metastatic solid tumors, and with recurrent ovarian and endometrial cancers. The gene discussed is MAP2K7; the disease is endometrial cancer.